MS & PHD STUDENTS

Mahdi Gharaibeh, PhD

Degree: 
PhD
Program: 
Pharmaceutical Sciences
Track: 
Pharmaceutical Economics, Policy and Outcome
Dissertation Title: 
Optimizing Economic Evaluation of First-line Chemotherapies for Metastatic Pancreatic Cancer for the UK and the US

Alumnus
Year Graduated: 2016
Manager, Global Health Economics at Amgen

Education
Jordan University of Science and Technology, Doctor of Pharmacy (2009) & University of Sheffield, MS (2012)

Honors & Achievements
1.Academic Excellence Award, University of Arizona, Pharmaceutical Economics Policy and Outcomes Track (2015)
2. Rho Chi Society member
3. Award of Excellence, Podium Presentation at Western Pharmacoeconomics and Outcomes Research Conference (2015)
 

Publications
1. Sun D, Gharaibeh M, Altyar A, MacDonald K, Martin J, Abraham I. Economic Evaluation of Primary Prophylaxis Using Filgrastim in Patients With Solid Tumor Cancer: A Systematic Literature Review. Value in Health 2014;17:A736.
2. Gharaibeh M, McBride A, Bootman JL, Abraham I. Economic Evaluation for the UK of Nab-Paclitaxel Plus Gemcitabine in The Treatment of Metastatic Pancreas Cancer. Br J Cancer. 2015 Mar 19.
3. Mahdi Gharaibeh, Ali McBride, J. Lyle Bootman, Lee D. Cranmer, Ivo Abraham. Economic Evaluation for the United States (US) of Gemcitabine (GEM), Nab-Paclitaxel Plus Gemcitabine (NAB-P+GEM), and FOLFIRINOX as First-Line Treatment for Metastatic Pancreatic Cancer (MPC). J Clin Oncol 33, 2015.
4. Gharaibeh M, Malone D. Economic Evaluation of Paclitaxel Albumin, Paclitaxel, and Docetaxel as Second Line Treatment in Metastatic Breast Cancer. Value in Health 2014; 17: A640.
5. Gharaibeh M, Bootman JL, McBride A, Martin J, Abraham I. Economic Evaluations of First-Line Chemotherapy Regimens for Pancreatic Cancer: A Critical Review. Pharmacoeconomics. 2016 Sep 14. [Epub ahead of print] Review. PubMed PMID: 27637757.
6. Mahdi Gharaibeh, Ali McBride, J. Lyle Bootman, Hitendra Patel, Ivo Abraham. Optimized economic evaluation for the United States (US) of nab-paclitaxel plus gemcitabine (NAB-P+GEM), FOLFIRINOX (FFX), and gemcitabine (GEM) as first-line treatment for metastatic pancreatic cancer (mPDA). J Clin Oncol 34, 2016 (suppl; abstr 4113)
7. Mahdi Gharaibeh, Ali McBride, J.Lyle Bootman, Hitendra Patel, Ivo Abraham. Weibull and exponential proportional hazard modelling for optimizing economic evaluations of cancer treatment: FOLFIRINOX (FFX) vs gemcitabine (GEM) in metastatic pancreas cancer (mPC). J Clin Oncol 34, 2016 (suppl; abstr e15704)
8. Ahmed Aljabri, Mahdi Gharaibeh, Yvonne Huckleberry, Hussam Kutbi, Seongseok Yun, Ivo Abraham, Brian Erstad. CostEffectiveness Evaluation for the US of Fondaparinux Compared to Argatroban in the Management of Suspected HIT. ASH 2015. (Abstract ID: 801708)
Originally posted: August 29, 2014
Last updated: February 2, 2017
Want to update? Contact Webmaster
Share This